Private Trust Co. NA Reduces Holdings in Icon Plc (NASDAQ:ICLR)

Private Trust Co. NA lowered its holdings in shares of Icon Plc (NASDAQ:ICLR) by 10.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,292 shares of the medical research company’s stock after selling 400 shares during the period. Private Trust Co. NA’s holdings in Icon were worth $549,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Credit Suisse AG boosted its stake in Icon by 220.0% during the 4th quarter. Credit Suisse AG now owns 41,033 shares of the medical research company’s stock worth $7,067,000 after purchasing an additional 28,209 shares during the period. BlackRock Inc. increased its holdings in Icon by 3.1% during the 1st quarter. BlackRock Inc. now owns 50,581 shares of the medical research company’s stock valued at $6,879,000 after acquiring an additional 1,541 shares in the last quarter. US Bancorp DE increased its holdings in Icon by 33.8% during the 1st quarter. US Bancorp DE now owns 11,992 shares of the medical research company’s stock valued at $1,631,000 after acquiring an additional 3,031 shares in the last quarter. State Street Corp increased its holdings in Icon by 23.3% during the 1st quarter. State Street Corp now owns 135,524 shares of the medical research company’s stock valued at $18,431,000 after acquiring an additional 25,612 shares in the last quarter. Finally, SHANDA ASSET MANAGEMENT HOLDINGS Ltd increased its holdings in Icon by 493.3% during the 1st quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd now owns 14,826 shares of the medical research company’s stock valued at $2,016,000 after acquiring an additional 12,327 shares in the last quarter. Hedge funds and other institutional investors own 82.71% of the company’s stock.

Shares of Icon stock opened at $171.88 on Thursday. The stock has a market capitalization of $9.22 billion, a P/E ratio of 24.69, a PEG ratio of 3.66 and a beta of 0.86. Icon Plc has a 12-month low of $104.28 and a 12-month high of $178.99. The stock has a 50 day moving average price of $163.81 and a two-hundred day moving average price of $160.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.05.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.02. Icon had a return on equity of 24.20% and a net margin of 13.26%. The firm had revenue of $715.10 million during the quarter, compared to analyst estimates of $711.07 million. During the same period in the prior year, the company posted $1.63 earnings per share. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. Sell-side analysts anticipate that Icon Plc will post 5.71 earnings per share for the current year.

Several equities analysts have weighed in on the stock. Robert W. Baird downgraded shares of Icon from an “outperform” rating to a “neutral” rating and set a $151.00 target price for the company. in a report on Monday, April 20th. Wells Fargo & Co dropped their target price on shares of Icon from $180.00 to $140.00 and set an “equal weight” rating for the company in a report on Monday, March 30th. Deutsche Bank dropped their target price on shares of Icon from $169.00 to $135.00 and set a “hold” rating for the company in a report on Friday, April 24th. Zacks Investment Research upgraded shares of Icon from a “sell” rating to a “hold” rating in a report on Tuesday, June 9th. Finally, Barclays lifted their price target on shares of Icon from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $161.83.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: Quiet Period Expirations Explained

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.